Tirzepatide vs Thymulin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | Thymulin |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. |
| Best For |